2020 Global Health & Medical Innovation Competition Awardees Announced; Several Projects Advance Toward IPO
In 2020, the formidable COVID-19 pandemic swept across the globe. In this battle against the epidemic, from laboratories to the front lines of outbreak response, we witnessed the “China speed” in translating scientific achievements into practical applications across pathogen detection, disease surveillance and early warning, rapid screening, clinical diagnosis and treatment, and the development of new drugs and vaccines.
To further promote the translation and commercialization of scientific and technological achievements in hygiene and health, as well as to foster the development of innovation and entrepreneurship projects in the healthcare industry, the Hangzhou Qiantang New Area Administrative Committee, the Talent Office of the Hangzhou Municipal Committee of the Communist Party of China, the Hangzhou Investment Promotion Bureau, and The First Affiliated Hospital, Zhejiang University School of Medicine jointly hosted the “Global Call for Healthcare Innovation and Entrepreneurship Projects” in March 2020.
Spanning three months, the initiative cast a wide net across the global healthcare sector, inviting submissions from fields such as biopharmaceuticals, medical devices, big data, and artificial intelligence. A total of 94 projects passed the initial screening; among these, 45 underwent further review by shortlisting committees and expert panels, ultimately earning the Crested Ibis Award after rigorous multi-stage selection.
The list of awardees is hereby announced as follows:
Public Notice Period: June 20, 2020 – June 26, 2020
During the public notice period, any entity or individual may submit comments and views regarding the listed candidates to the Competition Organizing Committee via email.
Competition Organizing Committee Email: GIPHI_hdt@vcbeat.net
Applicants of projects awarded the Crested Ibis Award are requested to check their emails, promptly contact the relevant departments to negotiate and sign the corresponding agreements, and accelerate the translation and industrialization of their entrepreneurial projects.
Contact Person of Relevant Department: Mr./Ms. Li; Contact Number: 0571-86871921
After the project, which has been awarded the Crested Ibis Award, is implemented in Hangzhou Qiantang New Area, it will receive innovative empowerment across multiple dimensions, including policy, technology, ecosystem, capital, and branding. The Administrative Committee of Hangzhou Qiantang New Area will provide comprehensive policy support and safeguards; eleven innovation service platforms, jointly established by Hangzhou Medicine Port and prestigious universities worldwide, will empower innovative projects with technological support; public service platforms such as the Innovation Translation Center of the First Affiliated Hospital of Zhejiang University School of Medicine, the Clinical Trial Center of the First Affiliated Hospital of Zhejiang University School of Medicine at Hangzhou Medicine Port, the Public Service Platform for Biopharmaceutical R&D at Hangzhou Medicine Port, and the Zhejiang Institute for Medical Device Testing will provide full-chain ecosystem empowerment to innovative projects.
Hangzhou Medicine Port focuses on four key sectors: biopharmaceuticals, medical devices, biomedical engineering, and healthcare big data. It has attracted seven of the top ten global pharmaceutical companies, including Pfizer, Merck & Co., Abbott, Eli Lilly, and Johnson & Johnson, and is home to more than 1,000 biopharmaceutical enterprises.Output value reached RMB 35 billion. By 2025, Hangzhou Medicine Port will gather more than 4,000 biopharmaceutical companies, with an output value of RMB 100 billion, and attract 200 leading talents in the biopharmaceutical field. It strives to establish a National Biopharmaceutical Innovation Center and build itself into a domestically leading and world-class hub for biopharmaceutical research and innovation.